Cargando…

Correction to: Eftrenonacog Alfa: A Review in Haemophilia B

Detalles Bibliográficos
Autores principales:	Lamb, Yvette N., Hoy, Sheridan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247548/ https://www.ncbi.nlm.nih.gov/pubmed/37222971 http://dx.doi.org/10.1007/s40265-023-01896-3

Ejemplares similares

Eftrenonacog Alfa: A Review in Haemophilia B
por: Lamb, Yvette N., et al.
Publicado: (2023)

Correction to: Efmoroctocog Alfa: A Review in Haemophilia A
por: Frampton, James E.
Publicado: (2021)

Correction to: Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Apixaban and eftrenonacog alfa treatment in a patient with moderate hemophilia B and cardiovascular disease
por: Santoro, Rita C., et al.
Publicado: (2021)

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management
por: Benitez Hidalgo, Olga, et al.
Publicado: (2022)

Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa
por: Rendo, Pablo, et al.
Publicado: (2018)

Correction to: Nonacog Beta Pegol: A Review in Haemophilia B
por: Syed, Yahiya Y.
Publicado: (2018)

Lonoctocog Alfa: A Review in Haemophilia A
por: Al-Salama, Zaina T., et al.
Publicado: (2017)

Efmoroctocog Alfa: A Review in Haemophilia A
por: Frampton, James E.
Publicado: (2021)

Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Correction to: Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
por: Hoy, Sheridan M.
Publicado: (2019)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy
por: Hoy, Sheridan M.
Publicado: (2021)

Correction to: MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
por: Hoy, Sheridan M.
Publicado: (2020)

Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2023)

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Correction to: Rozanolixizumab: First Approval
por: Hoy, Sheridan M.
Publicado: (2023)

Correction to: Fremanezumab: First Global Approval
por: Hoy, Sheridan M.
Publicado: (2019)

Correction to: Vestronidase Alfa: A Review in Mucopolysaccharidosis VII
por: McCafferty, Emma H., et al.
Publicado: (2019)

Correction: Teprotumumab: A Review in Thyroid Eye Disease
por: Nie, Tina, et al.
Publicado: (2022)

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Correction to: Efanesoctocog Alfa: First Approval
por: Keam, Susan J.
Publicado: (2023)

Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

Correction to: Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2020)

Correction to: Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Correction to: Viloxazine: Pediatric First Approval
por: Lamb, Yvette N.
Publicado: (2023)

Correction to: Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Correction to: Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B
por: Fukutake, Katsuyuki, et al.
Publicado: (2019)

Correction to: Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use
por: Lamb, Yvette N.
Publicado: (2019)

Correction to: Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia
por: Tiede, Andreas, et al.
Publicado: (2018)

Correction to: Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use
por: Heo, Young-A
Publicado: (2023)

Correction to: Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use
por: Syed, Yahiya Y.
Publicado: (2023)

Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study
por: Liesner, Ri J., et al.
Publicado: (2021)

Correction to: Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
por: Heo, Young-A
Publicado: (2018)

Correction to: The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review
por: Velthuis, Erica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sfnu58t6ahtf3smkoe9dhff92c